NetScientific PLC (NSCI) - Vortex Announces Partnership with BioView

NetScientific plc

("NetScientific" or the "Company" or the "Group")

Vortex Biosciences and BioView Announce Collaboration for Clinical Biomarker Identification on Circulating Tumor Cells

London, UK - 13 March 2018 -- ADVFN NewsWire -- NetScientific plc ("NetScientific",AIM:NSCI), the transatlantic healthcare IP commercialisation group, notes that its portfolio company, Vortex BioSciences, has announced a collaboration with BioView Ltd (TASE:BIOV), a provider of automated cell imaging and analysis solutions.

The collaboration will enable Vortex and Bioview to create integrated workflows that will allow the collection of intact CTCs from blood samples to become part of the standard of care, with a view to increasing the prominence of CTCs in the clinical space as a diagnostic and monitoring tool. The aim of the collaboration is to provide clinicians with deeper insights into cancer biology.

BioView (TLV: BIOV) is a publicly traded company on the Tel Aviv Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions. Bioview develops, manufactures and supplies cell imaging equipment, and analysis software to medical institutes and universities. It currently has several strategic collaborations with international scientific leaders and institutions. BioView's circulating tumour cell (CTC) application incorporates field-proven algorithms, developed in collaboration with leading cancer research centers worldwide.

The integrated VTX-1 and BioView workflow is currently being used in several clinical studies focused on CTC enumeration, ALK FISH rearrangements and PD-L1 expression on CTCs. PD-L1, in particular, has been a focus of the collaboration because of the potential clinical benefits. Overexpression of PD-L1 has been identified as a pathway that metastatic tumor cells use to evade immune detection.

Commenting on the news, Francois Martelet, Chairman of Vortex BioSciences Inc. and CEO of NetScientific said: "This partnership with BioView will allow automated identification of biomarkers expressed by CTCs collected by Vortex's platform. This technology has potential applications in the fast-evolving field of immuno-oncology and the collaboration represents a critical step for Vortex as it moves towards the clinical market."

# # #

For more information, please contact:

NetScientific François R. Martelet, M.D., CEO Ian Postlethwaite, CFO	Tel: [phone]
Consilium Strategic Communications Mary-Jane Elliott / Jessica Hodgson / Chris Welsh / Laura Thornton	Tel: [phone] [e-mail]
Stifel Nicolaus Europe Limited (NOMAD and Broker) Jonathan Senior / David Arch / Ben Maddison Vortex Biosciences Steve Crouse	Tel: [phone] Tel: [phone] [e-mail]

About NetScientific

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

MEDIA CONTACT
Steve Crouse
415-823-7649
[e-mail]